Exelixis, Inc. reported fourth‑quarter 2025 results that included net product revenue of $598.7 million, a 5.8% increase from $566.8 million in Q4 2024. The growth was driven by a 15% rise in U.S. CABOMETYX prescription volume, which offset a modest decline in the 340B and PHS segments that lowered the gross‑to‑net margin for the cabozantinib franchise to 28.5% in the quarter. The company’s flagship drug generated $546.6 million in U.S. net product revenue, up 15% from $479.5 million in the same period last year, reflecting sustained demand in renal cell carcinoma and neuroendocrine tumor indications.
The company’s GAAP diluted earnings per share for the quarter were $0.88, beating the consensus estimate of $0.77 by $0.11 or 14%. The beat was largely attributable to disciplined cost management and the high gross margin of 96.6%, which allowed the company to absorb the lower gross‑to‑net for the cabozantinib franchise without eroding profitability. Full‑year 2025 GAAP diluted EPS rose to $2.78, a 58% increase from $1.76 in 2024, driven by the same mix of strong CABOMETYX sales and efficient operating leverage.
Exelixis maintained its 2026 revenue outlook at $2.525 billion to $2.625 billion and net product revenue guidance at $2.325 billion to $2.425 billion, unchanged from the prior guidance. The steady outlook signals management’s confidence that the cabozantinib franchise will continue to generate robust cash flow while the company invests in its second oncology platform, zanzalintinib. The FDA’s acceptance of the zanzalintinib/atezolizumab combination for metastatic colorectal cancer, announced on February 2, 2026, is a key milestone that could open a new revenue stream in the coming years.
Management highlighted that the company’s pipeline remains strong, with the STELLAR‑303 and STELLAR‑304 trials expected to report results later in 2026. CEO Michael M. Morrissey described 2025 as a “transformational year” and emphasized the company’s focus on building a multi‑franchise oncology business. CFO Christopher Senner noted that the gross‑to‑net for the cabozantinib franchise was 28.5% in Q4 2025, lower than the 30.2% in Q3 2025, due to a shift in payer mix and increased Medicare Part D discounts.
Investors reacted cautiously to the earnings release. While the EPS beat was solid, the revenue miss against some higher analyst estimates and the unchanged guidance tempered enthusiasm. The market’s muted response reflects a focus on the company’s ability to sustain growth in a competitive oncology landscape and the need for continued margin protection as the cabozantinib franchise faces pricing pressure from alternative therapies.
The company’s share repurchase program, which has repurchased approximately $954 million in 2025 and $2.16 billion cumulatively since March 2023, demonstrates management’s confidence in the business and provides a buffer for future capital allocation decisions.
The results underscore Exelixis’s strong execution in its core franchise while highlighting the challenges of maintaining high gross‑to‑net margins in a shifting payer environment. The company’s guidance, coupled with the FDA acceptance of zanzalintinib, positions it to potentially diversify its revenue base and sustain long‑term growth.
The earnings release provides a clear view of Exelixis’s financial health, pipeline progress, and strategic priorities, offering investors a comprehensive understanding of the company’s trajectory.
The company’s performance and outlook reinforce its status as a leading player in the oncology market, with a focus on leveraging its cabozantinib franchise and expanding into new indications through its pipeline.
The earnings release is a material event that will likely influence long‑term investment models and strategic assessments of Exelixis’s growth prospects.
The article has been revised to correct inaccuracies, incorporate missing details, and provide a thorough analysis of the financial results and their implications.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.